Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05042193 Completed - Clinical trials for SARS-CoV-2 Acute Respiratory Disease

A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19

Start date: March 19, 2021
Phase:
Study type: Observational

The primary objective of this study is to describe the longevity of IgG against SARS-CoV-2 infection or vaccination.

NCT ID: NCT05041985 Completed - Whiplash Injuries Clinical Trials

Clinical Efficacy of Diazepam After Whiplash : A Randomized Controlled Study

Start date: January 1, 2020
Phase: Phase 4
Study type: Interventional

Whiplash injury is very common and lot of patients which suffered the injury have chronic symptoms despite different treatment options. One of main symptoms include muscle spasm and pain caused by neck movement. Diazepam is a well known drug which can be used to treat muscle spasms. The aim of this study is to determine whether short term Diazepam therapy can have positive effect on long term outcomes after whiplash injury.

NCT ID: NCT05040594 Completed - Clinical trials for Wrinkles Such as Nasolabial Folds

Evaluate the Efficacy and Safety of Lidocaine-Containing Hyaluronic Acid Filler in the Treatment of Nasolabial Folds.

Start date: December 26, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of PavéDerm J-fill soft dermal filler vs. Restylane® Lyft lidocaine in the treatment of moderate to severe nasolabial folds.

NCT ID: NCT05040438 Completed - Clinical trials for Locally Advanced Hepatocellular Carcinoma

Natural Killer (NK) Cell Therapy in Locally Advanced HCC

Start date: October 15, 2019
Phase: Phase 2
Study type: Interventional

This Phase 2a trial will evaluate the safety and efficacy of NK cell therapy combined with the hepatic artery infusion chemotherapy (HAIC) in patients with intermediate and/or locally advanced hepatocellular carcinoma (HCC). We hypothesized that 5-fluorouracil (FU) with immunomodulatory functions would relieve the immunosuppressive microenvironment from the myeloid-derived suppressor cells (MDSCs), thereby enhancing the anti-tumor activity of NK cells. Thus, the subsequent infusion of autologous NK cells (VAX-NK/HCC) following HAIC treatment may further improve the anti-tumor activity in patients with advanced HCC.

NCT ID: NCT05040347 Completed - Clinical trials for Portal Vein Tumor Thrombosis

Neutrophil Extracellular Traps as a Biomarker to Predict Portal Vein Tumor Thrombosis in Patients With Hepatocellular Carcinoma

Start date: August 18, 2020
Phase:
Study type: Observational

The aim of this study was to investigate whether NETs markers can enhance predict portal vein tumor thrombosis in patients with live cirrhosis, so as to establish a novel predictor to guide clinical decision-making.

NCT ID: NCT05040152 Completed - Clinical trials for Obesity-Related Malignant Neoplasm

Weight Loss Intervention for the Reduction of Cancer Risk and Health Disparities in Rural Ohio

HERO
Start date: November 6, 2021
Phase: N/A
Study type: Interventional

This study determines the feasibility of a telephone-based weight lost intervention in reducing cancer risk and health disparities in rural Ohio. Obesity is the leading preventable cause of cancer, and obesity-related inflammation is linked to elevated cancer risk, independent of obesity itself. Rural populations are a vulnerable population in need of increased access to tailored strategies and benefit from weight loss interventions. This study aims to see whether a telephone-based intervention may help obese people in rural area to reduce body weight, so as to prevent obesity-related cancer.

NCT ID: NCT05040139 Completed - Clinical trials for Fecal Incontinence With Fecal Urgency

A Comparison of Quality of Life Between MAlone Procedure and Percutaneaous Endoscopic Caecostomy in Patients With Antegrade Colonic Enema

MAPEC
Start date: November 13, 2018
Phase:
Study type: Observational [Patient Registry]

Background: Antegrade colonic enema (ACE) is a second intent treatment of severe constipation and/or fecal incontinence following the failure of medical treatment. ACE is classically administered through a percutaneous access to the caecum performed surgically according to the Malone procedure (MP). Recently, a novel endoscopic approach named Percutaneous Endoscopic Caecostomy (PEC) has been proposed to perform the percutaneous access to the caecum. PEC has never been compared to the traditional MP in terms of postoperative quality of life and functional outcomes. Objective: The aim of the study is to compare postoperative quality of life between MP and PEC in patients treated with ACE for severe constipation and/or fecal incontinence. Hypothesis: MP and PEC achieve similar quality of life outcomes. Methods: All patients from two prospective databases who underwent MP or PEC for severe constipation and/or fecal incontinence between 2006 and 2016 will be included. They will be contacted to answer questionnaires about quality of life (GIQLI) and functional outcomes including constipation, fecal incontinence and body image assessment (KESS, Wexner and BIQ scores respectively). The main measured outcome will be GIQLI score. Results: The results of this comparative study will determine if the endoscopic and the surgical approaches are similar in terms of quality of life, or if one of them is better than the other. This study will clarify the optimal protocol to perform a caecal percutaneous access before ACE administration in patients suffering from severe constipation and/or fecal incontinence.

NCT ID: NCT05038943 Completed - Clinical trials for Extracorporeal Membrane Oxygenation

Evaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart Transplantation

Start date: September 15, 2021
Phase: N/A
Study type: Interventional

This is a prospective, pilot trial to evaluate the safety and effectiveness of The Paragonix SherpaPak™ Cardiac Transport System ("SherpaPak CTS") in transportation of cardiac allografts recovered from donors after circulatory death with thoracoabdominal normothermic regional perfusion (TA-NRP). SherpaPak™ CTS is an ultraportable hypothermic preservation and transport system that has been approved by United States Food & Drug Administration (FDA) for clinical use in heart transplantation.

NCT ID: NCT05038566 Completed - Amputation Clinical Trials

Dexterous Partial Hand Prosthesis Outcomes

Start date: July 15, 2021
Phase: N/A
Study type: Interventional

Liberating Technologies, Inc. (LTI) has developed a dexterous prosthetic fingertip that will be fit onto an i-Digits™ partial hand prosthesis and allow for an additional fine grasp. The device will interface with research participants' existing prostheses and use the same control strategy that is used for their everyday use. Each participant's prosthesis will be restored to their original configuration by the end of their testing period.

NCT ID: NCT05038501 Completed - Clinical trials for Comorbidities and Coexisting Conditions

Prevalence of Comorbidities in Patients Undergoing Oncosurgeries at Tertiary Cancer Institute in North India.

oncosurgery
Start date: July 1, 2021
Phase:
Study type: Observational

Investigators plan to study the prevalence of comorbidities in patients undergoing oncosurgeries